PNTG Eyes November Earnings with Retail Attention Spiking and Shorts Creeping Higher

The Pennant Group heads into its November 6 results with two conflicting currents: short interest climbing at its fastest monthly pace in months while options traders lean unusually bullish.

Short interest has risen 26% over the past month, reaching 3.4% of the free float. That is still a modest absolute level, but the pace of accumulation is worth watching. The move accelerated through early October, peaked around October 9, then pulled back slightly before nudging higher again this week. At the same time, the borrow market remains relaxed. Cost to borrow is just 0.42%, and availability runs at nearly 2,900%, meaning there are roughly 29 shares available to lend for every one currently borrowed. Shorts face no squeeze pressure from the lending side. Options tell a different story from the short market. The put/call ratio has dropped to 0.49, nearly two standard deviations below its 20-day average of 0.52, placing calls firmly in the driving seat. That is the most call-heavy options reading in recent weeks, suggesting options traders are positioned for the upside rather than hedging against a miss.

The Street has been consistently constructive, lifting targets in each of the past three major analyst reviews. Wells Fargo and RBC both raised targets after the August print, while Truist pushed its target to $48 in July. The consensus mean sits around $47, implying roughly 12% above the current $41.88 close. The valuation is not cheap: the stock trades at a PE just above 27 and an EV/EBITDA near 18.4, with that EBITDA multiple drifting slightly higher over the past 30 days. The bull case rests on same-store momentum across home health, hospice, and senior living, with the company having raised full-year guidance to $1.17 to $1.19 billion in revenue and adjusted EBITDA of $94 to $98 million. Bears counter that the business leans heavily on Medicare reimbursement, that execution risk from rapid M&A remains real, and that FY27 EBITDA could fall 5% below current estimates under their scenario.

One alt-data signal stands out this week. PNTG's Wikipedia and ORTEX page views have spiked to a combined retail-attention z-score of 5.0, measured against the stock's own 90-day history. That is an unusually high reading. It reflects attention, not a revenue indicator, but the timing, 13 days before earnings, suggests new interest from retail investors discovering the name ahead of the print.

On the ownership side, the institutional register has been broadly supportive. BlackRock added 243,000 shares in the most recent quarter, reported to September 30. Goldman Sachs Asset Management added 256,000 shares, reported as of October 1. Wasatch Advisors and Vanguard Capital Management have both crossed the 5% threshold and filed Schedule 13G disclosures this year, none carrying activist intent. All 13D/G stakes are as last disclosed, and any holder dropping below 5% may not file again. Recent insider activity is noisier than it looks. Six directors received share grants on October 15, transaction type "A" rather than open-market purchases. These are compensation awards, not conviction buys, and carry limited signal. The meaningful insider trades were in August, when the CEO sold 4,285 shares at $38.52 in an open-market transaction not covered by a 10b5-1 plan, and the General Counsel sold a similar amount. Net insider activity over the past 90 days amounts to a sale of around 7,000 shares, worth roughly $272,000 combined.

The last two earnings prints produced muted day-one moves for PNTG, less than 1.5% in either direction, before a modest five-day drift lower in both cases. With the November 6 date approaching and retail attention elevated, the key variable is whether guidance for FY27 confirms or tempers the growth trajectory the Street has priced into a 27x earnings multiple.